Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Small Pharma Inc (OP: DMTTF ) N/A UNCHANGED Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Small Pharma Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD January 06, 2024 A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub Via Benzinga Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More October 29, 2023 Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted Via Benzinga Topics Intellectual Property Exposures Intellectual Property Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents October 26, 2023 Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) Via Benzinga Topics Intellectual Property Exposures Intellectual Property Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics October 23, 2023 Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. Via Benzinga InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector October 23, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics October 23, 2023 From Cybin Inc. Via Business Wire Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted October 22, 2023 Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts Via Benzinga Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business October 20, 2023 Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. Via Benzinga Small Pharma Reports Fiscal Second Quarter 2024 Highlights October 19, 2023 From Small Pharma Inc. Via GlobeNewswire Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement October 18, 2023 Short-acting psychedelics biotech Small Pharma Inc. Via Benzinga Small Pharma Obtains Final Order Approving Arrangement October 17, 2023 From Cybin Inc. Via Business Wire Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More October 16, 2023 Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Via Benzinga Exposures Product Safety Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates October 13, 2023 Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. Via Benzinga Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders October 12, 2023 From Small Pharma Inc. Via GlobeNewswire Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... Via Benzinga Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results September 26, 2023 New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. Via Benzinga Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More September 26, 2023 Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Via Benzinga Topics Economy Exposures Interest Rates Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder September 26, 2023 From Small Pharma Inc. Via GlobeNewswire Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression September 21, 2023 Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... Via Benzinga Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update September 18, 2023 Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). Via Benzinga Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT September 05, 2023 The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More September 05, 2023 Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Via Benzinga Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions August 31, 2023 Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka... Via Benzinga Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M August 29, 2023 Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9... Via Benzinga Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety August 28, 2023 Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o Via Benzinga Cybin to Acquire Small Pharma Inc. August 28, 2023 - All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for... Via Newsfile Topics Intellectual Property Exposures Intellectual Property InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’ August 28, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin to Acquire Small Pharma Inc. August 28, 2023 From Cybin Inc. Via Business Wire Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More August 03, 2023 A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... Via Benzinga Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial July 28, 2023 UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.